Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.67 |
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27986572 | 0.98 | FAAH (0.70) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL21096710 | 0.98 | FAAH (0.65) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL10140852 | 0.92 | FAAH (0.59) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL23471072 | 0.92 | FAAH (0.62) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL8515656 | 0.91 | FAAH (0.62) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL17974464 | 0.91 | FAAH (0.57) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL17817086 | 0.91 | FAAH (0.62) | FAAHCASP2NAAAEPHX1 | |
| SCHEMBL15613427 | 0.91 | FAAH (0.62) | FAAHCASP2NAAAEPHX1 | |
| SCHEMBL31213810 | 0.91 | FAAH (0.62) | FAAHCASP2NAAAEPHX1MEN1 | |
| SCHEMBL24622918 | 0.91 | FAAH (0.62) | FAAHCASP2NAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807674-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| EP-2968443-B1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10442846-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10407468-B2 | Methods for synthesizing α4β7 peptide antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190185536-A1 | HEPCIDIN ANALOGUES AND USES THEROF | ZEALAND PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185535-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-20180100004-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9822157-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20090131317-A1 | COMPOUNDS AND PEPTIDES THAT BIND THE TRAIL RECEPTOR | AFFYMAX, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185535-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | FAAH 3060/4885CASP2 2752/4885NAAA 2115/4885 |
| US-10407468-B2 | Methods for synthesizing α4β7 peptide antagonists | PSMA7, VIP, ITGB7 | FAAH 4426/4885CASP2 3973/4885NAAA 1817/4885 |
| US-20180100004-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | FAAH 3060/4885CASP2 2752/4885NAAA 2115/4885 |
| US-10442846-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | FAAH 3065/4885CASP2 2855/4885NAAA 2105/4885 |
| US-11807674-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | FAAH 3060/4885CASP2 2752/4885NAAA 2115/4885 |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | FAAH 3060/4885CASP2 2752/4885NAAA 2115/4885 |
| US-20190185536-A1 | HEPCIDIN ANALOGUES AND USES THEROF | HAMP, SLC40A1, FTH1 | FAAH 3306/4885CASP2 1728/4885NAAA 2484/4885 |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PSMA7, PSMA4, IL4 | FAAH 4781/4885CASP2 2809/4885NAAA 2275/4885 |
| US-20090131317-A1 | COMPOUNDS AND PEPTIDES THAT BIND THE TRAIL RECEPTOR | TNFSF10, TNFSF11, TNFRSF1A | FAAH 4295/4885CASP2 379/4885NAAA 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.